Ultime notizie per Apollomics (NASDAQ:APLM) Azioni

Apollomics

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Apollomics Inc. - Class A Ordinary Shares

Apollomics Inc

Lake Street analyst Eric Martinuzzi upgrades Brightcove (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>) from Hold to Buy and raises the price target from $2.75 to $3.5.

News

Upgrades

Price Target

Analyst Ratings

BCOV

Lake Street Upgrades Brightcove to Buy, Raises Price Target to $3.5

Deutsche Bank analyst Ross Seymore maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and raises the price target from $60 to $100.

ALAB

Deutsche Bank Maintains Buy on Astera Labs, Raises Price Target to $100

Deutsche Bank analyst Brian Bedell maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Buy and raises the price target from $65 to $67.

Deutsche Bank Maintains Buy on TPG, Raises Price Target to $67

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.

Reiteration

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

WIIM

TDUP

ThredUp shares are trading higher after the company reported better-than-expected Q3 EPS and sales and slightly raised its FY2024 sales guidance.

Deutsche Bank analyst Brian Bedell maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Hold and lowers the price target from $20 to $19.

Deutsche Bank Maintains Hold on Franklin Resources, Lowers Price Target to $19

Deutsche Bank analyst Brian Bedell maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Buy and raises the price target from $51 to $56.

Deutsche Bank Maintains Buy on Brookfield Asset Mgmt, Raises Price Target to $56

EGHT

8x8 shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

Deutsche Bank analyst Brian Bedell maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Buy and lowers the price target from $219 to $204.

Deutsche Bank Maintains Buy on Affiliated Managers Group, Lowers Price Target to $204

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Buy and maintains $70 price target.

IRON

HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target

Trio Petroleum Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>) shares are trading lower by 19% to 10 cents Tuesday morning after the company announced a <a href="https://www.benzinga.com/pressreleases/24/11/g41727117/trio-petroleum-corp-announces-reverse-stock-split">1-for-20 reverse stock split</a>, approved by its board and shareholders, to take effect on November 14. 
What To Know: This split will consolidate every 20 shares of common stock into 1 share, affecting all outstanding shares equally. Stockholders' ownership percentages will remain the same, though fractional shares will be rounded up. 
Adjustments will also be made to Trio's equity awards. The stock will begin trading on a post-split basis on November 15, under the same symbol (TPET) with a new CUSIP number.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a>
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TPET has a 52-week high of $0.72 and a 52-week low of $0.08.

TPET

Why Trio Petroleum (TPET) Stock Is Trading Lower

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and maintains $6 price target.

ATOS

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target

Trio Petroleum shares are trading lower after the company announced a 1-for-20 reverse stock split.

<ul>
<li>DJT</li>
<li>PLTR</li>
<li>SMCI</li>
<li>LOT</li>
<li>TSLA</li>
<li>NVDA</li>
<li>HIMS</li>
<li>AI</li>
<li>LINE</li>
<li>BA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LINE

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 5, 2024 (Via Swaggy Stocks)

Biotech

General

LYEL

Lyell To Present Initial Clinical Data From Phase 1-2 Trial Of IMPT-314 CAR T-Cell Therapy For B-Cell Lymphoma At ASH 2024, Highlighting Fast Track Designation And Dual-Targeting CD19/CD20 Approach

Barclays analyst Alex Scott maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Equal-Weight and raises the price target from C$76 to C$79.

TSX:SLF

Barclays Maintains Equal-Weight on Sun Life Financial, Raises Price Target to C$79

Bionomics Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares are trading higher by 177% to 53 cents Tuesday morning after the company announced it <a href="https://www.benzinga.com/pressreleases/24/11/g41727839/bionomics-receives-milestone-payment-of-aus-1m-from-carina-biotech-for-bnc101-partnered-legacy-onc">received a milestone payment</a> of AUD$1 million from Carina Biotech related to their partnered oncology program, BNC101.
What To Know: This payment aligns with their 2020 exclusive license agreement for BNC101, a monoclonal antibody targeting LGR5, a cancer stem cell antigen. 
Carina Biotech is developing an LGR5-targeted CAR-T therapy, CNA3103, for metastatic colorectal cancer, and Bionomics could earn up to AUD$118 million in further development, regulatory and commercial milestone payments if the therapy is fully developed and marketed.
Additionally, Bionomics is set to earn royalties on net sales and may receive a share of sublicensing revenue. Bionomics' CEO highlighted this payment as a testament to their research strength and noted the progress of their strategic partnership with Merck for an Alzheimer&#8217;s therapy, which could soon yield additional milestone payments.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a>
<h2 class="wp-block-heading">How To Buy BNOX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bionomics&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BNOX has a 52-week high of $2.84 and a 52-week low of $0.18.

BNOX

Why Bionomics (BNOX) Stock Is Up 100% Today

REQORSA Modulates In Vivo Immune Responses Against Cancers
AUSTIN, Texas, Nov. 5, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4294293-1&amp;h=152405195&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from a study of the Company's lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid)&nbsp;evaluating TUSC2's role in modulating immune responses in cancer. The poster will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting being held November 6-10, 2024 in Houston, Texas.

Penny Stocks

GNPX

Genprex Collaborators Present Preclinical Data On Reqorsa Gene Therapy At The Society For Immunotherapy Of Cancer 2024 Annual Meeting; REQORSA Modulates In Vivo Immune Responses Against Cancers

Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) has outperformed the market over the past 5 years by 5.75% on an annualized basis producing an average annual return of 18.82%. Currently, Brinker International has a market capitalization of $4.85 billion. 
Buying $1000 In EAT: If an investor had bought $1000 of EAT stock 5 years ago, it would be worth $2,342.45 today based on a price of $108.40 for EAT at the time of writing.
<h3>Brinker International's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817033_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today

CRKN

Crown Suspends Equity Line of Credit Agreement With Liqueous LP

Apollomics GAAP EPS of -$2.32

Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on CalciMedica (CALC – Research Report), Apollomics (AP...

Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)

These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Apollomics (APLM – Research Report) today and set a price target of $2.00. Robert B...

Maintaining Buy Rating on Apollomics Amid Clinical Setbacks and Pipeline Potential

Apollomics announces changes in executive leadership team

Apollomics receives 180-day extension to regain compliance with Nasdaq

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!



Moving stocks this morning are an acquisition deal, a clinical trial launch, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chuy&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/chuy-stock-quote/">CHUY</a>) stock is rocketing more than 46% on a <a href="https://www.nasdaq.com/press-release/darden-restaurants-acquire-chuys-holdings-inc-approximately-605-million-transaction">$605 million acquisition deal</a>.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) shares are soaring over 43% alongside heavy pre-market trading.</li>



<li>Apollomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/">APLM</a>) stock is surging more than 25% with strong early morning trading.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are rising over 23% as it <a href="https://www.nasdaq.com/press-release/bionomics-initiates-affirm-1-phase-3-clinical-trial-bnc210-social-anxiety-disorder">kicks off a Phase 3 clinical trial</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is increasing more than 18% with strong pre-market trading.</li>



<li>ZimVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/zimv-stock-quote/">ZIMV</a>) shares are heading over 13% higher without any clear news on Thursday morning.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) stock is gaining more than 12% on a <a href="https://www.globenewswire.com/news-release/2024/07/18/2914992/0/en/SAI-TECH-Global-Corporation-Announces-Share-Repurchase-Program.html">share repurchase program</a>.</li>



<li>MultiMetaVerse (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmv-stock-quote/">MMV</a>) shares are climbing over 11% as it continues a recent rally.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is jumping more than 10% despite a lack of news today.</li>



<li>XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) shares are up over 10% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Leslies (NASDAQ:<a href="https://investorplace.com/stock-quotes/lesl-stock-quote/">LESL</a>) stock is diving more than 21% on <a href="https://www.nasdaq.com/press-release/leslies-inc-announces-preliminary-third-quarter-fiscal-2024-financial-results-and">preliminary earnings and guidance</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) shares are rumbling over 13% after a massive rally yesterday.</li>



<li>Domino&rsquo;s Pizza (NYSE:<a href="https://investorplace.com/stock-quotes/dpz-stock-quote/">DPZ</a>) stock is sliding more than 13% with the release of its <a href="https://ir.dominos.com/static-files/68ecdbfc-bd1c-486a-a574-d6f54b7e5132">Q2 earnings report</a>.</li>



<li>CBL International (NASDAQ:<a href="https://investorplace.com/stock-quotes/banl-stock-quote/">BANL</a>) shares are taking an over 12% beating on Thursday morning as it retreats from a rally yesterday.</li>



<li>WiMi Hologram Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) stock is dropping close to 12% after an unexpected rally yesterday.</li>



<li>Beyond Meat (NASDAQ:<a href="https://investorplace.com/stock-quotes/bynd-stock-quote/">BYND</a>) shares are falling more than 11% on <a href="https://www.wsj.com/articles/beyond-meat-engages-bondholders-for-restructuring-talks-7de6b8ae">restructuring talks with bondholders</a>.</li>



<li>American Rebel (NASDAQ:<a href="https://investorplace.com/stock-quotes/areb-stock-quote/">AREB</a>) stock is decreasing over 11% this morning after rallying on Wednesday.</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are slipping more than 10% <a href="https://investorplace.com/2024/07/why-is-aditxt-adtx-stock-up-72-today/">following a rally yesterday</a>.</li>



<li>Stardust Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdst-stock-quote/">SDST</a>) stock is dipping over 10% <a href="https://investorplace.com/2024/07/stardust-power-sdst-stock-pops-140-days-after-debut-what-to-know/">after a surprise rally yesterday</a>.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Apollomics stock rallies 30% on Phase 2 vebreltinib data

Apollomics GAAP EPS of -$0.38

ABBV

ADAP

ADTX

APLM

APLMW

APVO

AREB

ASPHF

AUTL

BANL

BEIGF

BGNE

BMYMP

BYND

CALC

CHUY

CRTHF

DAWN

DCPH

DMPWW

DSKYF

DSNKY

GILD

GLAXF

INCY

IOVA

ITRM

JBPHF

KTRA

LESL

MDNAF

MPSYF

NVCR

NVSEF

ONCO

RCUS

REGN

RHHBF

RHHBY

RHHVF

SDST

SMMT

SNYNF

SPHRF

SPHRY

SRRK

TKPHF

WIMI

XWEL

ZIMV

Press Releases

Apollomics Announces Presentation at the 2024 BIO International Convention

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apollomics Announces Updated Strategic Focus and Leadership Team Changes

Markets

Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference

Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial

Biotech Sees Massive Buying Pressure Following Phase 2 Preliminary Data

Earnings

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024

Comments

Apollomics

Notizie

Ultime notizie per Apollomics (NASDAQ:APLM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO